As cardiac specialists and heart surgeons in the US gain confidence with the Heartware pump, its likely they will choose to use it for destination on their patients whether it has FDA approval or not. After BTT approval of course. If a patient needs to qualify via some criteria to apply for destination all their doctor needs to do is put them on the transplant wait list and implant them with the Heartware pump. They would then be on destination therapy. So when the FDA stop the go slow and bestow their approval for BTT onto Heartware we will then also have destination therapy. As I understand it, Heartmate are using the same pump for both therapies are they not? Heartware.. destined to be one of the stars of the decade.
HIN Price at posting:
$1.80 Sentiment: Buy Disclosure: Held
